Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AstraZeneca
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease
To evaluate the safety and tolerability of AZD5069 in patients with Chronic Obstructive Pulmonary Disease
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
AstraZeneca Pharmaceuticals
MAJ Il y a 5 ans
A Multicentre Randomised and Comparative Trial to Assess the Tolerance, Efficacy and Pharmacokinetics of Escalating Doses of Casodex Versus Castration in the Treatment of Advanced Carcinoma of the Prostate
Not provided at time of registration
Pays
United Kingdom
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A 24-week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Metformin or Metformin Combined with Fenofibrate) Study to Evaluate the Lipid Metabolic Effects, Glycaemic Effects, Safety and Tolerability of Tesaglitazar Therapy in Patients with Type 2 Diabetes and Low HDL-Cholesterol on a Fixed Background Therapy with a Statin
The two primary objectives of this study are to assess whether tesaglitazar is superior to metformin and non-inferior to metformin combined with fenofibrate in increasing high density lipoprotein-chol...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Phase III Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced Non-Small Cell Lung Cancer
To assess the efficacy of MEDI4736 treatment compared with placebo in terms of OS and PFS
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca Oy
MAJ Il y a 4 ans
A comparison of the efficacy of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 microg, one inhalation twice a day plus as-needed) and conventional best standard treatment for the treatment of persistent asthma in adolescents and adults. A randomised, open, parallel-group, multicentre, 26 weeks study
The primary objective is to compare the efficacy of Symbicort Single Inhaler Therapy with conventional best standard treatment in patients with persistent asthma.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A study to evaluate the efficacy and safety of dapagliflozin and dapagliflozin in combination with saxagliptin in type 2 diabetes with kidney disease. Ensayo para evaluar el efecto y la seguridad de dapaglifozina y dapaglifozina en combinación con saxagiptina en pacientes con diabetes tipo 2 con enfermedad renal crónica
Primary objectives for the Saxagliptin/Dapagliflozin treatment arm - To compare the mean change from baseline in HbA1c between dapagliflozin 10 mg plus saxagliptin 2.5 mg and placebo, after 24 weeks o...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB, European Regulatory Affairs
MAJ Il y a 4 ans
A double-Blind, Randomised, Placebo-Controlled, Multicentre, Dose-Escalating Study of AZD1305 Given Intravenoulsy for Cardioversion of Atrial Fibrillation
Primary safety objective: To evaluate the dose-response relationship for QT effects of AZD1305 Primary efficacy objective: To demonstrate a dose-response relationship for AZD1305 given intravenously f...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Phase III, Randomised, Double-Blind, Multi-Centre Parallel-Group Study to Assess the Efficacy of ZD6474 (ZACTIMA™ ) Versus Erlotinib (TARCEVA®) in Patients With Locally Advanced or Metastatic (Stage IIIB – IV) Non-Small Cell Lung Cancer (NSCLC) after Failure of at least One Prior Cytotoxic Chemotherapy
The primary objective of this study is to demonstrate an improvement in Progression Free Survival (PFS) for ZD6474 (ZACTIMA™ ) Versus Erlotinib (Tarceva®) in patients with locally advanced or metastat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A randomized, double-blind, placebo controlled, three-way crossover study exploring the efficacy of AZD3778 compared with placebo and an oral antihistamine (loratadine) in a model of seasonal allergic rhinitis
The primary objective of this study is to explore the efficacy of AZD3778 compared with placebo and an oral antihistamine, Loratadine, in relieving the symptoms of allergic rhinitis in a model of seas...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AstraZeneca AB
MAJ Il y a 4 ans
A Phase IIIb, efficacy, and safety study of rosuvastatin in children and adolescents 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH): a 12-week, double-blind, randomized, multi-center, placebo-controlled study with a 40-week, open-label, follow-up period
The primary objective of this study is to determine the efficacy of once-daily rosuvastatin in reducing LDL-C in children and adolescents aged 10-17 years with HeFH from baseline (Day 0) to the end of...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
17
18
19
20
21
22
23
24
25
26
Suivant